MedTrace Logo

Cord Blood Serum in the Treatment of Ocular Surface Diseases

NCT01234623 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2011-05-26

No results posted yet for this study

Summary

Human autologous serum (AS) eye drops have been successfully used in the treatment of severe ocular surface disorders and the enhancement of corneal wound healing, due to their growth factor (GF) content. Umbilical cord serum (UCS) contains even higher GF concentrations and the objective of the study was to prove whether UCS eye drops

1. are effective in the healing of corneal epithelial defects.
2. ameliorate the painful subjective symptoms

Conditions

  • Graft vs Host Disease
  • Sjogren's Disease

Interventions

OTHER

UCS eyedrops

1 ml UCS eyedrops/day topically applied 8 times/day 1 drop/eye for 28 days

Sponsors & Collaborators

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna

    lead OTHER

Principal Investigators

  • Emilio C Campos, MD · Head of Ophthalmology Unit, Dept.of Specialistic Surgery and Anesthesiological Sciences, University of Bologna, Policlinico S. Orsola-Malpighi, Pad 1 Palagi, Via Palagi 9 -40138 Bologna Italy

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01234623 on ClinicalTrials.gov